Select Page

Improving Patients Outcomes and Quality of life

COMBAT’s COMBAT’s highly qualified, medically trained, product specialists work closely with healthcare professionals worldwide to ensure the products bring benefit to as many patients as possible. With robust training & support programmes in place, Combat works alongside its highly experienced clinical advisory boards to advise and implement all clinical trial and R&D programmes.
“HIVEC ® offers a new treatment option for patients with high and intermediate risk bladder cancer. For patients where BCG is not tolerated, not available or has failed, HIVEC offers a promising well tolerated, alternative bladder preserving treatment in selected patients.”

Mr D Wilby, Consultant Urologist Portsmouth Hospitals NHS Trust.

Urology

Find out how we’re transforming Bladder Cancer treatments.

Surgical Oncology

Find out how we’re advancing Peritoneal Cancer treatments

“Trial results presented at AUA2020 show that CHT with MMC (HIVEC) little R) is not inferior to BCG in terms of efficacy and patients had milder side effects than those under BCG treatment”.

Felix Guerrero-Ramos, 12 Octubre Hospitral, Madrid. The Journal of Urology. Vol 203, No 4, May 2020

English EN Spanish ES